Watch-and-wait after PD-1 for certain rectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at whether people with a very strong response to a PD-1 antibody can safely delay or avoid more standard rectal cancer treatment (a “watch-and-wait” approach). It may help some people avoid surgery, radiation, or ongoing treatment while still closely monitoring the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma (rectal gland cancer) diagnosed by biopsy.
- Your tumor is dMMR or MSI-H (a specific DNA repair/genetic marker), confirmed by tumor testing.
- Your MRI shows the tumor is low in the rectum (below the peritoneal reflection).
- Your scans show no spread to distant organs (no distant metastasis on CT/MRI).
- You must have had a complete response: imaging suggests complete response and biopsy confirms no remaining tumor (cCR and pCR).
- You should not have had rectal surgery, chemotherapy, radiotherapy, or immune drugs like PD-1/PD-L1/CTLA-4 or other trial medicines before this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This study looks at whether some people with locally advanced rectal cancer can safely delay or avoid surgery after chemoradiation by closely monitoring tumors (“watch and wait”). It may help those who strongly want to preserve the anus, but only if they meet strict safety checks.
This study is for people with rectal cancer who have had treatment like radiation or chemo and their tumor has disappeared or nearly disappeared. Instead of surgery right away, doctors will closely monitor the cancer with regular check-ups to make sure it stays gone.
This trial tests a shorter course of radiation that avoids draining lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), for people with stage II or III rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink tumors while keeping lymph nodes intact.
This trial studies people with early-to-mid stage distal rectal cancer who may get radiation and chemotherapy, with an option that may include an extra drug (oxaliplatin). It also tests whether some people can safely follow a “watch and wait” plan instead of immediate additional treatment, aiming to reduce overtreatment while keeping cancer control.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.